BRAF drugs can give valuable extra months of quality life to about half of melanoma patients, but sadly it is not a cure and most patients eventually develop resistance. These new drugs are engineered ...
A mother who was spending £11,000 every three months to pay for her son's brain tumour medication has spoken of her relief ...
A mother who was spending thousands of pounds a month on medication to treat her son’s brain tumour speaks of her relief has ...
U.S. regulatory and commercial rights to tovorafenib for most common childhood brain tumor, pediatric low-grade glioma (pLGG) ...
Ipsen has signed yet another portfolio-expanding deal – its fifth of the year so far – claiming rights outside the US to a ...
Doctors typically prescribe these drugs when the cancer does not respond to other treatments. According to research, about 4% of people with NSCLS have a BRAF mutation. This causes a change to ...
No writing assistance was utilized in the production of this manuscript. BRAF, a member of a serine/threonine kinase protein family, serves as an immediate downstream effector of RAS in the MAPK ...
The clinical trial included three arms. Arm A treated patients who had the BRAF mutation with a combination of drugs called vemurafenib, cobimetinib and atezolizumab before surgery. Arm B included ...
A mother who was spending thousands of pounds a month on medication to treat her son’s brain tumour has spoken of her relief after the drug ...
So hundreds, rather than tens, of personalized cancer drugs. But considerable progress is already being made. The first oncogene to be identified by cancer genome sequencing was the kinase BRAF in ...
Researchers have found that among patients with certain melanoma, presurgical targeted therapy and immunotherapy can result ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback